GJIC
NVO

Gamble Jones Investment Counsel’s Novo Nordisk NVO Stock Holding History

Gamble Jones Investment Counsel’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7,060
Closed -$205K – 210
2015
Q4 		$205K Buy
+7,060
New +$195K 0.02% 201

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Gamble Jones Investment Counsel's NVO Position: Q1 2016 in Review

Gamble Jones Investment Counsel sold out of Novo Nordisk (NVO) in Q1 2016, closing a stake of 7,060 shares — an estimated $205K sold.

Gamble Jones Investment Counsel first reported a position in NVO in Q4 2015 and held it in 1 quarter. The position peaked at $205K in Q4 2015. 536 funds tracked by Wall St. Rank hold NVO as of Q1 2016.

  • Gamble Jones Investment Counsel reported no remaining Novo Nordisk position as of Q1 2016 after selling out during the quarter.
  • Gamble Jones Investment Counsel sold 7,060 Novo Nordisk shares in Q1 2016, an estimated $205K.
  • Gamble Jones Investment Counsel first reported a position in Novo Nordisk in Q4 2015 and held it in 1 quarter.
  • Gamble Jones Investment Counsel's Novo Nordisk position peaked at $205K in Q4 2015.
  • 536 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2016.

Based on Gamble Jones Investment Counsel's 13F filing for Q1 2016, filed 2 May 2016.